Christian Weyer

Christian Weyer, President and Chief Medical Officer, joined Escient in May 2021. Dr. Weyer has held executive leadership positions in several private and publicly traded companies, where he contributed to the development, approval, and/or lifecycle management of several first-in-class medicines for diabetes (Byetta®, Bydureon®, Symlin®), lipodystrophy (Myalept®), and cholestatic liver disease (Ocaliva®). Prior to joining Escient, Dr. Weyer served as Executive VP of R&D at Intercept Pharmaceuticals (2017-2021), President and Chief Development Officer at ProSciento (2015-2017), and as President and Chief Executive Officer of Fate Therapeutics (2012-2015). Previously, he held roles of increasing responsibilities at Amylin Pharmaceuticals (2001-2012), most recently as Senior Vice President of R&D, until the acquisition of the company by BMS.

Dr. Weyer received his M.D. and clinical training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany, holds a postdoctoral master’s degree in advanced clinical research from the University of California, San Diego, and conducted post-doctoral research at the National Institutes of Health.